Meta-Analysis of Mortality in Dialysis Patients With an Implantable Cardioverter Defibrillator††Disclosures: Dr. Bhatt has received research grants (directly to the institution) from Bristol-Myers Squibb, New York, New York; Eisai Inc., Woodcliff Lake, New Jersey; Ethicon, Inc., Somerville, New Jersey; Heartscape Technologies, Inc., Columbia, Maryland; Sanofi-Aventis, Paris, France; and The Medicines Company, Parsippany, New Jersey. Dr. Bhatt is a consultant for or member of the advisory boards (honoraria waived or donated to nonprofit organizations) of Arena Pharmaceuticals, Inc., San Diego, California; AstraZeneca PLC, London, United Kingdom; Bristol-Myers Squibb; Cardax Pharmaceuticals, Inc., Aiea, Hawaii; Centocor, Inc., Horsham, Pennsylvania; Cogentus Pharmaceuticals, Palo Alto, California; Daiichi Sankyo, Inc., Parsippany, New Jersey; Eisai Inc.; Eli Lilly and Company, Indianapolis, Indiana; GlaxoSmithKline PLC, London, United Kingdom; Johnson & Johnson, New Brunswick, New Jersey; Ortho-McNeil, Raritan, New Jersey; Medtronic, Inc., Minneapolis, Minnesota; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts; Otsuka Pharmaceutical Company, Ltd., Tokyo, Japan; ParinGenix, Inc., Weston, Florida; PDL BioPharma, Inc., Redwood City, California; Philips Medical Systems, Andover, Massachusetts; Portola Pharmaceuticals Inc., South San Francisco, California; Sanofi-Aventis; Schering-Plough Corporation, Kenilworth, New Jersey; The Medicines Company; and Vertex Pharmaceuticals, Inc., Cambridge, Massachusetts.